Analysis of a capsid-modified and conditionally replicating, oncolytic adenoviral vector as a novel treatment for human glioblastoma multiforme.

Analysis of a capsid-modified and conditionally replicating, oncolytic adenoviral vector as a novel treatment for human glioblastoma multiforme.

Glioblastoma multiforme (GBM) is the most aggressive brain tumor, and patients rarely survive for more than 2 years. Gene therapy may offer new treatment options and improve the prognosis for patients with GBM. Adenovirus-mediated gene therapy strategies for brain tumors have been limited by ineffic...

詳細記述

保存先:
書誌詳細
第一著者: Wohlfahrt, Martin E.
その他の著者: Lingelbach, Klaus (Prof.) (論文の指導者)
フォーマット: Dissertation
言語:英語
出版事項: Philipps-Universität Marburg 2010
主題:
TRAIL
Glioblastoma multiforme, TRAIL
Oncolysis
Adenovirus
Onkolyse
Glioblastom
Adenovirus 5
Naturwissenschaften
Natural sciences & mathematics
オンライン･アクセス:PDFフルテキスト
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
その他の書誌記述
要約:Glioblastoma multiforme (GBM) is the most aggressive brain tumor, and patients rarely survive for more than 2 years. Gene therapy may offer new treatment options and improve the prognosis for patients with GBM. Adenovirus-mediated gene therapy strategies for brain tumors have been limited by inefficient gene transfer due to low expression of the adenovirus serotype 5 (Ad5) receptor. We have used an adenovirus vector that specifically replicates in tumor cells and uses an Ad5 capsid and the adenovirus serotype (Ad35) fiber for efficient infection of malignant tumor cells. This vector also expresses adenovirus E1A and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a tumor-specific manner. Here, we show that this oncolytic vector (Ad5/Ad35.IR-E1A/TRAIL) efficiently infects the GBM tumor cell lines SF767, T98G, and U-87 MG. Tumor cell killing was markedly enhanced with Ad5/Ad35.IR-E1A/TRAIL compared with wild-type Ad5 and Ad35 virus or Ad5/Ad35.IR-E1A- vectors without TRAIL expression in vitro. In vivo experiments using s.c. xenografted U-87 MG cells in NOD/SCID mice showed a significant growth delay of tumors after i.t. injection of Ad5/Ad35.IR-E1A/TRAIL, whereas adenovirus wild-type injections showed only marginal or no effect. Our findings indicate that the use of a capsid-modified adenoviral vector, in combination with TRAIL expression, is a promising novel approach for gene therapy of glioblastoma.
DOI:10.17192/z2010.0644

類似資料